ArticleEye and brain2021
Evaluation of Retinal Layer Thickness Parameters as Biomarkers in a Real-World Multiple Sclerosis Cohort.
Article in Eye and brain, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Retinal Optical Coherence Tomography Longitudinal Measures as Prognostic Biomarkers in Multiple Sclerosis: Systematic Review and Meta-Analysis.Neurology(R) neuroimmunology & neuroinflammation · 2025Pooled it
- Amyotrophic lateral sclerosis and retinal changes in optical coherence tomography: A systematic review and meta-analysis.Brain and behavior · 2022Pooled it
- Cup-to-Disc Ratio Is Associated with Disability in Multiple Sclerosis: A Combined OCT and Subjective Visual Vertical Study.Medicina (Kaunas, Lithuania) · 2026Article
- Reliability of Macular Ganglion Cell-Inner Plexiform Layer Thickness Measurements Across Scan Protocols in Spectral-Domain Optical Coherence Tomography.Journal of clinical medicine · 2026Article
- Retinal nerve fiber layer thinning in multiple sclerosis: clinical implications, cognitive associations, and effects of disease-modifying therapies.Journal of neurology · 2025Article
- Application of optical coherence tomography in multiple sclerosis: consensus recommendations of the Austrian network (AN-OCT-MS).Journal of neurology · 2025Article
- Ensemble learning-based method for multiple sclerosis screening from retinal OCT images.Medical & biological engineering & computing · 2025Article
- Longitudinal Analysis of P100 Wave Amplitude and Latency in Multiple Sclerosis: A 19-Year Retrospective VEP Study.Diagnostics (Basel, Switzerland) · 2025Article
- Anatomy-driven segmentation of parafoveal optical coherence tomography (OCT) measures may improve associations with clinical outcomes in multiple sclerosis.Journal of neurology · 2025Article
- Paramagnetic rim lesions are associated with inner retinal layer thinning and progression independent of relapse activity in multiple sclerosis.European journal of neurology · 2025Article
- Oculomic stratification of COVID-19 patients' intensive therapy unit admission status and mortality by retinal morphological findings.Scientific reports · 2024Article
- Evolution of retinal degeneration and prediction of disease activity in relapsing and progressive multiple sclerosis.Nature communications · 2024Article
- Swept-Source Optical Coherence Tomography Thresholds in Differentiating Clinical Outcomes in a Real-World Cohort of Treatment-Naïve Multiple Sclerosis Patients.Brain sciences · 2023Article
- Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis.International journal of molecular sciences · 2023Review
- Retinal imaging with optical coherence tomography in multiple sclerosis: novel aspects.Wiener medizinische Wochenschrift (1946) · 2022Review
- Comparison of Machine Learning Methods Using Spectralis OCT for Diagnosis and Disability Progression Prognosis in Multiple Sclerosis.Annals of biomedical engineering · 2022Article
- Optical coherence tomography assessment of axonal and neuronal damage of the retina in patients with familial and sporadic multiple sclerosis.Frontiers in neurology · 2022Article
- Association of Cerebrospinal Fluid Parameters and Neurofilament Light Chain With Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis.Frontiers in neurology · 2022Article
- Citicoline: A Candidate for Adjunct Treatment of Multiple Sclerosis.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Regional retinal vulnerability in multiple sclerosis: integrating OCT, MRI, and clinical data for enhanced diagnosis and automated monitoring.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRetinal layer thickness parameters measured by optical coherence tomography (OCT) are emerging biomarkers of neuroaxonal degeneration and inflammation in multiple sclerosis (MS). We aimed to evaluate the value of retinal layer thickness for prediction of disability worsening and relapse in a real-world MS cohort. PATIENTS AND
methodsFor this longitudinal observational study, we included MS patients with spectral-domain OCT scans available and ≥1 year of clinical follow-up. The value of peripapillary retinal nerve fiber layer (pRNFL), macular ganglion-cell-and-inner-plexiform-layer (GCIPL) and inner nuclear layer (INL) thickness for prediction of disability worsening and relapse during the observation period was tested by multivariate models.
resultsWe analyzed 60 MS patients during a mean observation period of 2.9 years (SD 1.8). Lower baseline thickness of GCIPL (cut-off <77µm; HR 4.1, p=0.001) and pRNFL (cut-off ≤88µm; HR 3.1, p=0.019) were associated with an increased risk of disability worsening. Longitudinally, mean thinning rates were -0.8µm/year (SD 1.6) for GCIPL, -0.6µm/year (SD 3.5) for pRNFL. GCIPL thinning ≥1.0µm/year and pRNFL >1.5µm/year is associated with higher likelihood of disability worsening (HR 5.7, p=0.009 and HR 6.8, p=0.003, respectively). INL thickened in patients with relapse by a mean 0.9µm while thinning by 0.3µm in patients without relapse (p=0.04). In multivariate analyses, INL thickening was associated with an increased probability of relapse (OR 17.8, p=0.023).
conclusionCross-sectional and longitudinal measurement of GCIPL and pRNFL thinning is reliable as a biomarker of disability worsening in a real-world setting. Change of INL thickness is a promising marker of relapse, i.e. inflammatory activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.